Results 1 to 10 of about 1,937,987 (265)

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

open access: goldHaematologica, 2010
Background The risk of thromboembolic events in adults with primary immune thrombocytopenia has been little investigated despite findings of increased susceptibility in other thrombocytopenic autoimmune conditions.
Ameet Sarpatwari   +7 more
doaj   +3 more sources

Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy [PDF]

open access: yesFuture Science OA, 2020
Background: Immune-related adverse events are associated with efficacy of immune checkpoint inhibitors (ICIs). We hypothesize that immune-mediated thrombocytopenia could be a biomarker for response to ICIs.
Hussein A Assi   +4 more
doaj   +3 more sources

Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors [PDF]

open access: yesScientific Reports
Immune checkpoint inhibitors (ICIs) have become an important treatment modality for various malignancies. Due to excessive inflammatory and immune responses, immune-related adverse events (irAEs), such as rash, pruritis, pneumonitis, hepatitis ...
Diwei Mo   +6 more
doaj   +2 more sources

The Centenary of Immune Thrombocytopenia—Part 2: Revising Diagnostic and Therapeutic Approach [PDF]

open access: yesFrontiers in Pediatrics, 2017
Primary immune thrombocytopenia (ITP) is the most common cause of thrombocytopenia in children and adolescents and can be considered as a paradigmatic model of autoimmune disease. This second part of our review describes the clinical presentation of ITP,
Rita Consolini   +2 more
doaj   +4 more sources

Acute lower‐extremity arterial thrombosis with immune thrombocytopenia [PDF]

open access: yesClinical Case Reports
Key Clinical Message We describe an acute lower‐extremity arterial occlusion in a 30‐year‐old woman with immune thrombocytopenia and polycystic ovary syndrome. Thrombosis may be a complication of immune thrombocytopenia requiring careful management.
Takahiro Nagatomo   +3 more
doaj   +2 more sources

Success of Helicobacter pylori Eradication Therapy and Long Lasting Platelet Recovery in an Iranian Patient with Severe Immune Thrombocytopenia [PDF]

open access: yesJournal of Kerman University of Medical Sciences, 2021
Background: Helicobacter pylori is a gram-negative spirochete that usually affects the gastric mucosa and has a prevalence of more than 50% of people worldwide.
Esmaeil Shahabi Satlsar   +5 more
doaj   +1 more source

COVID-19-associated immune thrombocytopenia [PDF]

open access: yesRomanian Journal of Infectious Diseases, 2021
The coronavirus disease 2019 (COVID-19) is a contagious respiratory tract infection caused by the betacoronavirus SARS-CoV-2. The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020.
Mara-Andrada Plesu   +4 more
doaj   +1 more source

Understanding Immune Thrombocytopenia: Looking Out of the Box

open access: yesFrontiers in Medicine, 2021
The pathogenesis of immune thrombocytopenia (ITP) is increasingly being elucidated, and its etiology is becoming more frequently identified, leading to a diagnostic shift from primary to secondary ITP.
Alexandra Schifferli   +8 more
doaj   +1 more source

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

open access: yesNew England Journal of Medicine, 2021
Background Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe acute respiratory syndrome coronavirus 2. Data are lacking on the clinical features of
S. Pavord   +8 more
semanticscholar   +1 more source

How we treat primary immune thrombocytopenia in adults

open access: yesJournal of Hematology & Oncology, 2023
Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding.
Xinguang Liu, Yu Hou, M. Hou
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy